Cetrorelix: A Fertility Drug that Shows Promise to Treat Pregnant Women with PCOS in the Future

Cetrorelix: A Fertility Drug that Shows Promise to Treat Pregnant Women with PCOS in the Future

Polycystic Ovarian Syndrome
Hormonal Agent, Synthetic Peptide

Cetrorelix CAS No: 120287-85-6


Cetrorelix is traditionally used as fertility API that binds to a hormone receptor to stop gonadotropin secretion. While it may be associated with women undergoing ovarian stimulation, it appears as though there’s more to this API that meets the eye. This synthetic decapeptide is being studied to help with a variety of conditions, including the stimulation of HDL in men and preventing PCOS in pregnant women. While many of these benefits still need additional confirmation, the potential for cetrorelix may go far beyond just helping infertile women.

Inhibiting Gonadotropin

Women may experience any number of trouble when trying to get pregnant. If their ovulation cycle can’t regulate on its own, then Cetrorelix can be given to help control the release of their hormones so they can produce multiple eggs. Specifically, Cetrorelix controls the luteinizing and the follicle-stimulating hormones to prevent premature ovulation prior to a doctor’s treatment for ovarian stimulation. The more time the egg is given the mature, the more likely it is that the implantation will happen. This drug is able to be used with follitropin alfa (for egg production) without risk to the women’s safety or her ability to become pregnant.

Testosterone Suppression

Cetrorelix has also been observed to lower testosterone levels in men while simultaneously boosting the ‘good’ cholesterol HDL. Over a period of three weeks, researchers compared a small group of men taking Cetrorelix against a control group, only to find that those who were taking Cetrorelix had lower testosterone levels and improved counts of high density lipoproteins by the end of their treatment. For those looking to prevent prostate cancer and sharpen their cardiovascular health, this API could be an effective way to kill two birds with one stone.

Polycystic Ovarian Syndrome and Pregnancy

Polycystic Ovarian Syndrome (PCOS) is not only a common cause of infertility, it can also threaten the life of a pregnant mother or her child. This health condition impacts up to 20% of adult women, and the current treatment it is not only complicated to administer but it’s also not a cure for the condition. Recently though, scientists tested the theory that PCOS is caused by an increase in the anti-Müllerian hormone. Using pregnant mice as subjects, they used cetrorelix as a way of confirming their hypothesis and vastly reducing the symptoms of PCOS. In the future, we may see pregnant women with PCOS given cetrorelix to improve their health and well-being during pregnancy.

LGM Pharma

LGM Pharma is an innovation-driven API company, involved in the distribution of quality cGMP pharma ingredients to leading pharmaceutical companies. We specialize in streamlining the API supply chain management throughout all development and commercial stages while providing complete technical capabilities, expert regulatory support as well as other value-added services.







  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service